Monitoring candidate gene expression variations before, during and after a first major depressive episode in a 51-year-old man

BMC Psychiatry

El Chérif Ibrahim¹  Jean-Michel Azorin¹  Raoul Belzeaux¹ 

[1] FondaMental, Fondation de Recherche et de Soins en Santé Mentale, Créteil, France

关键词: Major depression;    Antidepressant;    TNF;    5HTT;    Biomarker;    mRNA;   

Others  :  1123710
DOI  :  10.1186/1471-244X-14-73

 received in 2014-01-15, accepted in 2014-03-10,  发布年份 2014

【 摘 要 】

Background

Although psychiatric disorders are frequently characterized by clinical heterogeneity, high recurrence, and unpredictable prognosis, studies of mRNA expression variations in blood cells from psychiatric patients constitute a promising avenue to establish clinical biomarkers. We report here, to our knowledge, the first genetic monitoring of a major depressive episode (MDE).

Case presentation

The subject is a 51-year-old male, who was healthy at baseline and whose blood mRNA was monitored over 67 weeks for expression variations of 9 candidate genes. At week 20 the subject experienced a mild to moderate unexpected MDE, and oral antidepressant treatment was initiated at week 29. At week 36, the patient recovered from his MDE. After 6 months, antidepressant treatment was discontinued and the subject remained free of depressive symptoms. Genetic monitoring revealed that mRNA expression of SLC6A4/5HTT increased with the emergence of a depressive state, which later returned to basal levels after antidepressant treatment and during MDE recovery. PDLIM5, S100A10 and TNF mRNA showed also an interesting pattern of expression with regards to MDE evolution.

Conclusion

This case demonstrated the applicability of peripheral mRNA expression as a way to monitor the natural history of MDE.

【 授权许可】

   
2014 Belzeaux et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]de Leon J: Pharmacogenomics: the promise of personalized medicine for CNS disorders. Neuropsychopharmacology 2009, 34(1):159-172.
• [2]Porcelli S, Drago A, Fabbri C, Gibiino S, Calati R, Serretti A: Pharmacogenetics of antidepressant response. J Psychiatry Neurosci 2011, 36(2):87-113.
• [3]Pajer K, Andrus BM, Gardner W, Lourie A, Strange B, Campo J, Bridge J, Blizinsky K, Dennis K, Vedell P, Churchill GA, Redei EE: Discovery of blood transcriptomics markers for depression in animal models and pilot validation in subjects with early-onset major depression. Transl Psychiatry 2012, 2:e101.
• [4]Niculescu AB, Le-Niculescu H: Convergent functional genomics: what we have learned and can learn about genes, pathways, and mechanisms. Neuropsychopharmacology 2010, 35(1):355-356.
• [5]Mamdani F, Berlim MT, Beaulieu MM, Turecki G: Pharmacogenomic predictors of citalopram treatment outcome in major depressive disorder. World J Biol Psychiatry 2014, 15(2):135-144.
• [6]Belzeaux R, Formisano-Treziny C, Loundou A, Boyer L, Gabert J, Samuelian JC, Feron F, Naudin J, Ibrahim EC: Clinical variations modulate patterns of gene expression and define blood biomarkers in major depression. J Psychiatr Res 2010, 44(16):1205-1213.
• [7]Spijker S, Van Zanten JS, De Jong S, Penninx BW, van Dyck R, Zitman FG, Smit JH, Ylstra B, Smit AB, Hoogendijk WJ: Stimulated gene expression profiles as a blood marker of major depressive disorder. Biol Psychiatry 2010, 68(2):179-186.
• [8]Mamdani F, Berlim MT, Beaulieu M-M, Labbe A, Merette C, Turecki G: Gene expression biomarkers of response to citalopram treatment in major depressive disorder. Transl Psychiatry 2011, 1:e13.
• [9]Yi Z, Li Z, Yu S, Yuan C, Hong W, Wang Z, Cui J, Shi T, Fang Y: Blood-based gene expression profiles models for classification of subsyndromal symptomatic depression and major depressive disorder. PLoS One 2012, 7(2):e31283.
• [10]Munkholm K, Vinberg M, Berk M, Kessing LV: State-related alterations of gene expression in bipolar disorder: a systematic review. Bipolar Disord 2012, 14(7):684-696.
• [11]Belzeaux R, Bergon A, Jeanjean V, Loriod B, Formisano-Treziny C, Verrier L, Loundou A, Baumstarck-Barrau K, Boyer L, Gall V, Gabert J, Nguyen C, Azorin JM, Naudin J, Ibrahim EC: Responder and nonresponder patients exhibit different peripheral transcriptional signatures during major depressive episode. Transl Psychiatry 2012, 2:e185.
• [12]Ruijter JM, Pfaffl MW, Zhao S, Spiess AN, Boggy G, Blom J, Rutledge RG, Sisti D, Lievens A, De Preter K, Derveaux S, Hellemans J, Vandesompele J: Evaluation of qPCR curve analysis methods for reliable biomarker discovery: bias, resolution, precision, and implications. Methods 2013, 59(1):32-46.
• [13]Cattaneo A, Gennarelli M, Uher R, Breen G, Farmer A, Aitchison KJ, Craig IW, Anacker C, Zunsztain PA, McGuffin P, Pariante CM: Candidate genes expression profile associated with antidepressants response in the GENDEP study: differentiating between baseline ‘predictors’ and longitudinal ‘targets’. Neuropsychopharmacology 2013, 38(3):377-385.
• [14]Tsao CW, Lin YS, Chen CC, Bai CH, Wu SR: Cytokines and serotonin transporter in patients with major depression. Prog Neuropsychopharmacol Biol Psychiatry 2006, 30(5):899-905.
• [15]Iga J, Ueno S, Yamauchi K, Motoki I, Tayoshi S, Ohta K, Song H, Morita K, Rokutan K, Ohmori T: Serotonin transporter mRNA expression in peripheral leukocytes of patients with major depression before and after treatment with paroxetine. Neurosci Lett 2005, 389(1):12-16.
• [16]Alexander B, Warner-Schmidt J, Eriksson T, Tamminga C, Arango-Lievano M, Ghose S, Vernov M, Stavarache M, Musatov S, Flajolet M, Svenningsson P, Greengard P, Kaplitt MG: Reversal of depressed behaviors in mice by p11 gene therapy in the nucleus accumbens. Sci Transl Med 2010, 2(54):54ra76.
• [17]Zhang L, Su TP, Choi K, Maree W, Li CT, Chung MY, Chen YS, Bai YM, Chou YH, Barker JL, Barrett JE, Li XX, Li H, Benedek DM, Ursano R: P11 (S100A10) as a potential biomarker of psychiatric patients at risk of suicide. J Psychiatr Res 2011, 45(4):435-441.
• [18]Melas PA, Rogdaki M, Lennartsson A, Bjork K, Qi H, Witasp A, Werme M, Wegener G, Mathe AA, Svenningsson P, Lavebratt C: Antidepressant treatment is associated with epigenetic alterations in the promoter of P11 in a genetic model of depression. Int J Neuropsychopharmacol 2012, 15(5):669-679.
• [19]Wong ML, Dong C, Andreev V, Arcos-Burgos M, Licinio J: Prediction of susceptibility to major depression by a model of interactions of multiple functional genetic variants and environmental factors. Mol Psychiatry 2012, 17(6):624-633.
• [20]Iga J, Ueno S, Yamauchi K, Numata S, Motoki I, Tayoshi S, Kinouchi S, Ohta K, Song H, Morita K, Rokutan K, Tanabe H, Sano A, Ohmori T: Gene expression and association analysis of LIM (PDLIM5) in major depression. Neurosci Lett 2006, 400(3):203-207.
• [21]Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK, Lanctot KL: A meta-analysis of cytokines in major depression. Biol Psychiatry 2010, 67(5):446-457.
• [22]Spitzer RL, Williams JBW, Gibbon M: Structured clinical interview for DSM-III-R, patient edition/non-patient edition, (SCID-P/SCID-NP). Washington, D.C.: American Psychiatric Press; 1990.
• [23]Begemann M, Sargin D, Rossner MJ, Bartels C, Theis F, Wichert SP, Stender N, Fischer B, Sperling S, Stawicki S, Wiedl A, Falkai P, Nave KA, Ehrenreich H: Episode-specific differential gene expression of peripheral blood mononuclear cells in rapid cycling supports novel treatment approaches. Mol Med 2008, 14(9–10):546-552.
• [24]Gibney SM, Drexhage HA: Evidence for a dysregulated immune system in the etiology of psychiatric disorders. J Neuroimmune Pharmacol 2013, 8(4):900-920.
• [25]Dantzer R, O’Connor JC, Freund GG, Johnson RW, Kelley KW: From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 2008, 9(1):46-56.
• [26]Dantzer R, O’Connor JC, Lawson MA, Kelley KW: Inflammation-associated depression: from serotonin to kynurenine. Psychoneuroendocrinology 2011, 36(3):426-436.
• [27]Miller AH, Haroon E, Raison CL, Felger JC: Cytokine targets in the brain: impact on neurotransmitters and neurocircuits. Depress Anxiety 2013, 30(4):297-306.
• [28]Warner-Schmidt JL, Vanover KE, Chen EY, Marshall JJ, Greengard P: Antidepressant effects of selective serotonin reuptake inhibitors (SSRIs) are attenuated by antiinflammatory drugs in mice and humans. Proc Natl Acad Sci U S A 2011, 108(22):9262-9267.
• [29]Sibille E, Lewis DA: SERT-ainly involved in depression, but when? Am J Psychiatry 2006, 163(1):8-11.
• [30]Menke A, Arloth J, Putz B, Weber P, Klengel T, Mehta D, Gonik M, Rex-Haffner M, Rubel J, Uhr M, Lucae S, Deussing JM, Müller-Myhsok B, Holsboer F, Binder EB: Dexamethasone stimulated gene expression in peripheral blood is a sensitive marker for glucocorticoid receptor resistance in depressed patients. Neuropsychopharmacology 2012, 37(6):1455-1464.
• [31]Menke A, Klengel T, Rubel J, Bruckl T, Pfister H, Lucae S, Uhr M, Holsboer F, Binder EB: Genetic variation in FKBP5 associated with the extent of stress hormone dysregulation in major depression. Genes Brain Behav 2013, 12(3):289-296.